Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Guardant Health, Inc.

NASDAQ: GH · Industrial Applications and Services · 7 alerts · CIK 1576280

Share price
$144.03Close, Nov 16
Market cap
$19.5B
Shares outstanding
135.29MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Guardant Health, Inc. filings on SEC EDGAR ↗

4:13 PM ET 8-K
Financial Results

Guardant Health Financial Results

Guardant Health reported Q3 2026 revenue of $361.0 million, a 36% increase year-over-year, driven by strong performance in its Oncology and Screening segments. The company raised its full-year 2026 revenue guidance to a range of $1.36 billion to $1.37 billion and highlighted the FDA approval of Guardant360 CDx as a companion diagnostic for breast cancer.

Term
Q3 2026

“Revenue grew 36% year over year as we continued to execute across Oncology, Screening, and Biopharma. Oncology volume grew 58% with broad contributions across our portfolio. The FDA approval of Guardant360 CDx for longitudinal ESR1 testing is a major advance for breast cancer patients, ushering in a new paradigm of cancer treatment. It reinforces the role of Guardant360 in enabling earlier therapy decisions and strengthens our leadership across the cancer care continuum.”

Helmy Eltoukhy, co-founder and co-CEO

“Shield continued to build momentum in the third quarter, with volume more than tripling year over year to 83,000 tests. Commercial coverage continues to expand, with recent policy updates extending Shield coverage to approximately 100 million lives. With our lower COGS, higher-throughput workflow now fully implemented, we have a strong operational foundation to meet future Shield demand. Together, these advances expand access to Shield and move us closer to making blood-based cancer screening a routine part of preventive care.”

AmirAli Talasaz, co-founder and co-CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.